AI-Driven Advancements in Neuroblastoma Diagnosis and Bone/Bone Marrow Metastasis Prediction
Groundbreaking Study Unveils Key Mechanisms in Neuroblastoma Bone and Bone Marrow Metastasis
EINPresswire.com / -- Neuroblastoma (NB), the most prevalent extracranial solid tumor among children, is characterized by a high rate of metastasis. The pathogenesis of NB with bone or bone marrow metastasis (NB-BBM) and its complex immune microenvironment remain poorly understood, posing challenges for effective risk prediction for BBM and limiting therapeutic strategies.
This research, published in the Genes & Diseases journal by a team from The Children's Hospital of Chongqing Medical University, highlights key genomic and single-cell transcriptomic alterations in NB-BBM, underscoring the significance of predictive pathology for NB-BBM and its role in understanding tumor onset, progression, and heterogeneity.
The researchers used a Swin-Transformer deep learning model to analyze 142 paraffin-embedded hematoxylin-eosin-stained tumor section images to predict NB-BBM occurrence, achieving a classification accuracy exceeding 85%. In parallel, single-cell transcriptomics identified a tumor cell subpopulation (NB3) and two tumor-associated macrophage (TAM) subpopulations (SPP1+ TAMs and IGHM+ TAMs) closely associated with BBM progression. Interestingly, findings reveal that oxidative phosphorylation (OXPHOS) also plays a crucial role in BBM development.
Additionally, this study highlighted transketolase (TKT) as a crucial metabolic molecule linked to BBM. The researchers showed that the TKT gene was strongly associated with the clinical features of NB patients, especially in the BBM group. Functional experiments validated TKT's involvement in malignant behavior, while pathway enrichment analysis showed correlations between high TKT expression and cell cycle activity.
Moreover, expression analysis of immune checkpoint genes CD274, LAG3, and TIGIT revealed their significant upregulation in NB-BBM, suggesting potential targets for antibody-based immunotherapies. Furthermore, immunohistochemical validation demonstrated a pronounced expression of PD-L1 in NB-BBM, indicating its potential as a biomarker.
Although this research provides a predictive model for NB-BBM risk assessment, it has certain limitations, including the need for multicenter validation of the predictive model and prospective studies to confirm clinical utility. Despite these challenges, this study offers a pathodiagnostic prediction for the risk of NB-BBM, enhances other imaging diagnoses, and elucidates the cellular heterogeneity of initial, progressive, and distant metastatic sites in NB.
Reference
Title of the original paper - Integrated multi-omics characterization of neuroblastoma with bone or bone marrow metastasis
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI: https://doi.org/10.1016/j.gendis.2024.101511
Funding Information:
Key Project of the National Key R&D Plan 'Research on Prevention and Control of Major Chronic Non-Communicable Diseases' (China)
Ministry of Science and Technology of the People's Republic of China
National Key R&D Program of China (No. 2018YFC1313000, 2018YFC1313004)
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
# # # # # #
CN: 50-1221/R
Genes & Diseases
+86 23 6571 4691
X
LinkedIn
Instagram
YouTube
Other
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
6 hours ago
- San Francisco Chronicle
New COVID variant linked to painful ‘razor blade throat' symptom
As summer brings another rise in COVID-19 infections, patients across Asia, Europe and North America are reporting a searing sore throat so intense it has earned a dramatic nickname: ' razor blade throat.' Though not a new symptom, the phenomenon has gained fresh attention amid the spread of a fast-moving Omicron subvariant, formally known as NB.1.8.1 and colloquially as 'Nimbus.' Patients in China and elsewhere describe the pain as akin to 'swallowing shattered glass,' with some saying they've been left unable to speak, eat, or even stay hydrated. 'Post-COVID razor blade throat is brutal — swollen, painful, and I can barely speak,' one user wrote on Weibo, China's leading social media platform, according to Chinese-language media. Another said, 'I've been hit with razor blade throat and feel completely drained.' Despite the visceral nickname, health experts emphasize that the symptom is not unique to this latest wave. 'Sore throat is a common symptom of COVID and not novel at all, and not associated with any one variant, including NB.1.8.1,' said Dr. Peter Chin-Hong, an infectious disease specialist at UCSF. 'There has been a range of intensity of sore throat with COVID symptoms all along, including very severe pain.' He noted that up to 70% of people infected with COVID-19 report a sore throat. Other common symptoms include fatigue, mild cough, fever, muscle aches, and congestion — all consistent with earlier strains of the virus. 'Current data do not indicate that this variant leads to more severe illness than other variants in circulation,' according to the World Health Organization, which last month designated NB.1.8.1 as a SARS-CoV-2 ' variant under monitoring.' The agency noted, however, that the subvariant appears more immune-evasive than the dominant LP.8.1 lineage. In China, where the current wave began in March, cases are expected to peak by late June. The NB.1.8.1 variant has since been detected in over 20 countries, including the United Kingdom and the United States, with early outbreaks noted in California, Washington and New York. Last month, an average of about 250 people died each week from COVID-19, according to data from the Centers for Disease Control and Prevention. Doctors continue to urge the public to stay up to date on vaccinations and take precautions, especially those in high-risk groups. 'To me, it is a reminder that even if you don't end up in urgent care or in the hospital, COVID can still make you very sick in 2025,' Chin-Hong said. 'As the summer approaches, we will likely see another wave of infections, likely fueled by variants like NB.1.8.1. Wastewater is already showing a bump in some areas in California and the US.' With COVID-19 expected to remain a persistent — if more manageable — presence, health officials continue to emphasize a familiar message: masks, handwashing, vaccination, and staying home when sick remain the best defense, razor blade throat or not. For those experiencing severe throat pain, Chin-Hong recommends over-the-counter treatments like ibuprofen or acetaminophen.
Yahoo
9 hours ago
- Yahoo
New Covid Variant Causes Sore Throat That Feels Like 'Razor Blades'
A new variant of the virus that causes Covid-19 is circulating, and is believed to be more contagious than previous mutations The variant, NB.1.8.1, has been informally dubbed "Nimbus," and causes a severe sore throat that's been likened to "razor blades" This latest mutation has been called a "strong candidate for the summer surge" of Covid casesA new variant of the virus that causes Covid-19 has already caused a surge in cases in Asia — and its signature symptom is a severe sore throat that feels like 'razor blades.' Covid variant NB.1.8.1 — which has informally been dubbed 'Nimbus' — is being monitored by the World Health Organization as this latest mutation of the wildly contagious virus already makes up more than 10% of cases in Asia, Salon reports, adding that it's now been detected in the United States, Europe, and Canada. The variant has a high 'immune evasion, supporting its potential for future dominance,' according to a pre-print study that has not yet been peer-reviewed. This strain, Salon reports, causes 'razor blade throat,' or a severe sore throat; Other symptoms include traditional flu-like symptoms like congestion, fatigue, a mild cough, fever, and muscle aches, and more infrequently diarrhea and nausea, The Independent reports. Per that outlet, WHO says global risk is 'currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.' But as Dr. Rajendram Rajnarayanan, of the New York Institute of Technology, told Salon, 'NB.1.8.1 is a strong candidate for the summer surge.' 'I know that everybody wants to forget about this disease, but it's not going to allow us to,' Dr. Janko Nikolich, Professor and Chair of the Department of Immunobiology at the University of Arizona College of Medicine said, according to ABC Action News. The news comes amid the Trump administration, under Health and Human Services Secretary Robert F. Kennedy Jr., rolling back Covid vaccine recommendations for children and pregnant women. Newborn babies are better protected against the virus if their mother receives the vaccine, Dr. Steven J. Fleischman, president of the American College of Obstetricians and Gynecologists, said in a statement, per NPR. "The science has not changed," he said. "It is very clear that COVID infection during pregnancy can be catastrophic and lead to major disability." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
Yahoo
9 hours ago
- Yahoo
What to know about the new ‘Nimbus' COVID variant
The World Health Organization (WHO) is keeping an eye on a new COVID-19 variant called NB.1.8.1, or 'Nimbus,' that has spread across Europe, the Americas and the Western Pacific. Nimbus is a descendant of the Omicron variant of the virus and was first identified in late January. Its spike mutations appear to make it more transmissible than other COVID-19 variants, according to the WHO. Spike mutations refer to changes in spike proteins, which sit on the surface of the virus and help it enter healthy cells. While it is spreading in the U.S. and Canada, along with 20 other countries, it does not appear to be driving an increase in sickness or hospitalization. In April, NB.1.8.1 sequences made up 10.7 percent of all submitted sequences from confirmed COVID infections, up from 2.5 percent a month earlier, according to a risk evaluation released by the WHO. The WHO last month deemed NB.1.8.1 a variant 'under monitoring.' Here's what to know about the variant. Most cases of COVID-19 in the U.S. still stem from the LP.8.1 strain, another Omicron descendant. But it looks like NB.1.8.1 might soon replace it as the more common strain, according to data from the Centers for Disease Control and Prevention (CDC). The CDC estimates that 37 percent of COVID-19 cases in the U.S. stem from the NB.1.8.1 variant, while 38 percent are a result from an infection of the LP.8.1 strain of the disease. At the end of May, the agency estimated the NB.1.8.1 variant caused about 15 percent of all COVID-19 cases. But the agency notes on its website that due to low numbers of virus sequences being reported, precision in the most recent reporting period is low. The NB.1.8.1 variant has been found in at least 13 states, according to Today, which cited data from the Global Initiative on Sharing All Influenza Data (GISAID) database. Those states are: California, New York, New Jersey, Maryland, Arizona, Illinois, Hawaii, Massachusetts, Ohio, Rhode Island, Vermont, Virginia and Washington. The available data on 'Nimbus' suggests it poses a low global threat and that existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization, according to the WHO. 'Currently approved COVID-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease,' the WHO's risk evaluation reads. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation.' Lionel Gresh, an international consultant at the WHO, told The Hill that many new cases in Canada are likely linked to the NB.1.8.1 variant, but that there has not been any major changes in the country in terms of cases, hospitalizations, ICU admissions or deaths linked to COVID-19. Symptoms of NB.1.8.1 seem to be similar to those associated with other Omicron variants, according to Gresh. Some common COVID-19 symptoms include cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting, and a new loss of smell or taste, according to the CDC. 'We should be as concerned about [NB.1.8.1] as we are concerned for COVID in general,' Gresh said. 'Not more, not less.' Some recent COVID-19 patients have reported experiencing something called 'razor blade throat,' according to Salon. But it is unclear if that symptom is connected to one of the COVID variants or another respiratory illness circulating, Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, told Salon. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
